Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05920356 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Name: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) — clinical trial record (NCT05920356)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2023-11-16

View on ClinicalTrials.gov ↗

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Amendment history 6 changes detected by DataLookout

2026-08-14

Trial sites expanded: 407 → 412 locations

2026-08-07

Trial sites expanded: 404 → 407 locations

2026-07-17

Trial sites expanded: 383 → 401 locations

2026-05-15

Trial sites expanded: 380 → 383 locations

2026-04-21

Primary completion pushed: 2026-06-30 → 2027-06-30

2026-04-21

Completion pushed: 2031-06-30 → 2032-06-29

Trial Details

NCT Number	NCT05920356
Lead Sponsor	Amgen
Conditions	Non-Small Cell Lung Cancer (NSCLC)
Enrollment	750 participants
Start Date	2023-11-16
Primary Completion	2027-06-30 (estimated)
Study Completion	2032-06-29 (estimated)
Updated on ClinicalTrials.gov	2026-08-27